HC Wainwright Reiterates “Buy” Rating for Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $3.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 66.67% from the stock’s previous close.

A number of other brokerages also recently issued reports on CGTX. B. Riley reaffirmed a “buy” rating and issued a $3.00 price target (up from $2.00) on shares of Cognition Therapeutics in a report on Friday, November 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Price Performance

NASDAQ:CGTX opened at $1.80 on Thursday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The firm has a market capitalization of $158.89 million, a PE ratio of -3.75 and a beta of 1.23. The business’s fifty day moving average price is $1.63 and its 200 day moving average price is $1.23.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. As a group, equities analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Cognition Therapeutics

A number of large investors have recently bought and sold shares of CGTX. Northeast Financial Consultants Inc grew its position in Cognition Therapeutics by 158.6% during the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock worth $27,000 after purchasing an additional 38,851 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Cognition Therapeutics by 814.1% in the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after buying an additional 897,353 shares during the last quarter. DAVENPORT & Co LLC acquired a new stake in shares of Cognition Therapeutics during the third quarter worth about $3,631,000. CWA Asset Management Group LLC purchased a new position in shares of Cognition Therapeutics during the third quarter worth about $34,000. Finally, McAdam LLC purchased a new position in shares of Cognition Therapeutics during the third quarter worth about $97,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.